Is it Time to Dump Inhibikase Therapeutics Inc (IKT) Stock After it Is Down 1.44% in a Week?

The market has been high on Inhibikase Therapeutics Inc (IKT) stock recently. IKT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Inhibikase Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IKT!

See Full IKT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With IKT Stock Today?

Inhibikase Therapeutics Inc (IKT) stock is down -2.14% while the S&P 500 is higher by 0.24% as of 9:34 AM on Wednesday, Oct 4. IKT has fallen -$0.03 from the previous closing price of $1.40 on volume of 3,867,964 shares. Over the past year the S&P 500 is up 15.25% while IKT has fallen -74.68%. IKT lost -$4.17 per share in the over the last 12 months.

More About Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Click Here to get the full Stock Report for Inhibikase Therapeutics Inc stock.